Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients
Figure 2
The changes in mean central retinal thickness in the bevacizumab group and ranibizumab group. The graph shows the mean central retinal thickness levels from baseline to the most recent followup. The change in mean central retinal thickness from the baseline to months 3, 6, 9, 12, and the last visit (Last) was not statistically different between the two groups ( for all).
